Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dow Jones

2024-11-06

       income              4,925          884        12,069        2,168 
                      ----------    ---------    ----------    --------- 
Net loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) 
                      ==========    =========    ==========    ========= 
Net loss per share 
 attributable to 
 common 
 stockholders, 
 basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) 
                      ==========    =========    ==========    ========= 
Weighted average 
 common shares 
 outstanding, basic 
 and diluted          18,884,562    9,039,427    17,210,604    5,763,121 
                      ==========    =========    ==========    ========= 
 
Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact: 
Dan Ferry 
Life Science Advisors 
Daniel@lifesciadvisors.com 
617-430-7576

(END) Dow Jones Newswires

November 06, 2024 07:30 ET (12:30 GMT)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2481603596"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481603596\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481603596?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481603596","market":"us","top_or_hot":-1,"title":"Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n       income              4,925          884        12,069        2,168 \n                      ----------    ---------    ----------    --------- \nNet loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) \n                      ==========    =========    ==========    ========= \nNet loss per share \n attributable to \n common \n stockholders, \n basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) \n                      ==========    =========    ==========    ========= \nWeighted average \n common shares \n outstanding, basic \n and diluted          18,884,562    9,039,427    17,210,604    5,763,121 \n                      ==========    =========    ==========    ========= \n \nInvestor Contact: \nPraxis Precision Medicines \ninvestors@praxismedicines.com \n857-702-9452 \n \nMedia Contact: \nDan Ferry \nLife Science Advisors \nDaniel@lifesciadvisors.com \n617-430-7576 \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2024 07:30 ET (12:30 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-06 20:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n       income              4,925          884        12,069        2,168 \n                      ----------    ---------    ----------    --------- \nNet loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) \n                      ==========    =========    ==========    ========= \nNet loss per share \n attributable to \n common \n stockholders, \n basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) \n                      ==========    =========    ==========    ========= \nWeighted average \n common shares \n outstanding, basic \n and diluted          18,884,562    9,039,427    17,210,604    5,763,121 \n                      ==========    =========    ==========    ========= \n \nInvestor Contact: \nPraxis Precision Medicines \ninvestors@praxismedicines.com \n857-702-9452 \n \nMedia Contact: \nDan Ferry \nLife Science Advisors \nDaniel@lifesciadvisors.com \n617-430-7576 \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2024 07:30 ET (12:30 GMT)\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481603596","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481603596","pubTimestamp":1730896200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor  confirmed for Q1 2025; NDA filing anticipated in 2025. Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies . Vormatrigine  on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025. Mr. Souza continued, \"Our ENERGY program for vormatrigine  is moving forward with strong interest, driven by insights from the ongoing observational EMPOWER study, and we are on track with our RADIANT and POWER1 trials. Additionally, we are actively exploring lifecycle expansion opportunities in Parkinson's Disease and pain. With strong financial and clinical positioning, we are set to build on this momentum, advancing all four clinical programs towards registrational readiness in 2025.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","ODD":"ODDITY Tech Ltd.","MDCO":"麦迪逊医药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","PRAX":"Praxis Precision Medicines, Inc.","TM":"丰田汽车","BK4561":"索罗斯持仓","BK4097":"系统软件","BK4581":"高盛持仓","BK4135":"资产管理与托管银行","BK4183":"个人用品","BK4590":"PTP","BK4200":"专卖店","BK4099":"汽车制造商","03160":"华夏日股对冲","ET":"Energy Transfer LP","ASO":"Academy Sports & Outdoors, Inc.","BK4144":"石油与天然气的储存和运输","CNS":"科恩-斯蒂尔斯金融","BK4585":"ETF&股票定投概念","RPD":"Rapid7, Inc.","BK4139":"生物科技","BK4555":"新能源车"},"translate_title":"新闻稿：Praxis Precision Medicines提供公司最新动态并报告2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03160":0.6,"ASO":1,"CNS":1,"ET":1,"MDCO":1,"ODD":1,"PRAX":1,"RPD":1,"TM":1},"content_text":"income              4,925          884        12,069        2,168 \n                      ----------    ---------    ----------    --------- \nNet loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) \n                      ==========    =========    ==========    ========= \nNet loss per share \n attributable to \n common \n stockholders, \n basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) \n                      ==========    =========    ==========    ========= \nWeighted average \n common shares \n outstanding, basic \n and diluted          18,884,562    9,039,427    17,210,604    5,763,121 \n                      ==========    =========    ==========    ========= \n \nInvestor Contact: \nPraxis Precision Medicines \ninvestors@praxismedicines.com \n857-702-9452 \n \nMedia Contact: \nDan Ferry \nLife Science Advisors \nDaniel@lifesciadvisors.com \n617-430-7576 \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2024 07:30 ET (12:30 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}